It stimulates blood vessel and nerve outgrowth and increases collagen, elastin, and glycosaminoglycan synthesis
Conclusions Our findings do not support an increased risk of intestinal obstruction in T2DM patients prescribed GLP-1 RAs compared to other anti-diabetic medications
Originally developed to manage type 2 diabetes, this GLP-1 receptor agonist has shown exceptional promise in tackling the global obesity epidemic
Notably, tirzepatide exhibits a preference for GIP receptors, leading to effective reduction of hyperglycemia and positive effects on pancreatic -cells
Results from a phase 2 randomized, placebo-controlled trial of liraglutide (1.23.0 mg) in 564 obese non-diabetic adults demonstrated that liraglutide 3.0 mg was statistically significantly more effective than orlistat, or diet and exercise alone, at reducing weight over 20 and 52 weeks, and weight loss was dose-dependent